Stay updated on CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma
Sign up to get notified when there's something new on the CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma page.

Latest updates to the CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedA new version of the clinical trial record was submitted on November 2, 2026, and posted the following day, with a change to the study status.SummaryDifference0.3%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedA site-wide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears, and the site revision changes from v3.7.1 to v3.7.2.SummaryDifference0.5%

- Check35 days agoChange DetectedThe site footer revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check56 days agoChange DetectedA new revision entry v3.7.0 has been added to the record history, and the previous revision v3.6.6 has been removed.SummaryDifference0.1%

- Check70 days agoChange DetectedThe header of the Record History page now shows Revision: v3.6.6, replacing the previous v3.6.5. This reflects a minor frontend/backend update to the history view without altering the underlying study information.SummaryDifference0.1%

- Check92 days agoChange DetectedA new revision entry v3.6.5 appears in the study's history with a Study Status update. This indicates the record has been revised and the trial's status has been updated within the official history.SummaryDifference0.3%

Stay in the know with updates to CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma
Enter your email address, and we'll notify you when there's something new on the CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma page.